KR970002876B1 - 피리다지논 유도체 - Google Patents

피리다지논 유도체 Download PDF

Info

Publication number
KR970002876B1
KR970002876B1 KR1019910701537A KR910701537A KR970002876B1 KR 970002876 B1 KR970002876 B1 KR 970002876B1 KR 1019910701537 A KR1019910701537 A KR 1019910701537A KR 910701537 A KR910701537 A KR 910701537A KR 970002876 B1 KR970002876 B1 KR 970002876B1
Authority
KR
South Korea
Prior art keywords
group
straight
alkyl group
branched
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019910701537A
Other languages
English (en)
Korean (ko)
Other versions
KR920701169A (ko
Inventor
게이조 다니까와
아끼라 사이또
다까시 마쓰모또
료조 사꼬다
노부또모 쓰루조에
겐이찌 사까다
Original Assignee
닛산가가꾸고오교 가부시끼가이샤
나까이 다께오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛산가가꾸고오교 가부시끼가이샤, 나까이 다께오 filed Critical 닛산가가꾸고오교 가부시끼가이샤
Publication of KR920701169A publication Critical patent/KR920701169A/ko
Application granted granted Critical
Publication of KR970002876B1 publication Critical patent/KR970002876B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1019910701537A 1990-04-25 1991-04-19 피리다지논 유도체 Expired - Lifetime KR970002876B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10991490 1990-04-25
JP90-109914 1990-04-25
PCT/JP1991/000517 WO1991016314A1 (en) 1990-04-25 1991-04-19 Pyridazinone derivative

Publications (2)

Publication Number Publication Date
KR920701169A KR920701169A (ko) 1992-08-11
KR970002876B1 true KR970002876B1 (ko) 1997-03-12

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701537A Expired - Lifetime KR970002876B1 (ko) 1990-04-25 1991-04-19 피리다지논 유도체

Country Status (17)

Country Link
US (3) US5202323A (https=)
EP (1) EP0482208B1 (https=)
JP (1) JPH07107055B2 (https=)
KR (1) KR970002876B1 (https=)
AT (1) ATE194835T1 (https=)
AU (1) AU634655B2 (https=)
CA (1) CA2053863C (https=)
DE (1) DE69132329T2 (https=)
DK (1) DK0482208T3 (https=)
ES (1) ES2149761T3 (https=)
GR (1) GR3034331T3 (https=)
HU (1) HU208124B (https=)
RU (1) RU2054004C1 (https=)
TW (1) TW204348B (https=)
UA (1) UA27031A1 (https=)
WO (1) WO1991016314A1 (https=)
ZA (1) ZA913134B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149761T3 (es) * 1990-04-25 2000-11-16 Nissan Chemical Ind Ltd Derivado de piridazinona.
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
AU681694B2 (en) * 1993-09-06 1997-09-04 Ishihara Sangyo Kaisha Ltd. Pyridazinone derivatives or their salts, processes for theirproduction, and anti-shock agents containing them
NZ270130A (en) * 1993-12-16 1995-12-21 Nihon Nohyaku Co Ltd Pyridazinone derivatives, preparation and pharmaceutical compositions thereof
DK0742211T3 (da) * 1994-01-25 2000-08-14 Nissan Chemical Ind Ltd Pyridazinonderivater
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
CN1102593C (zh) 1996-06-27 2003-03-05 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
US6284758B1 (en) * 1997-08-28 2001-09-04 Welfide Corporation Angiogenesis promoters and angiogenesis potentiators
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
DE69919191T2 (de) * 1998-09-01 2005-07-28 Nissan Chemical Industries, Ltd. Heilmittel für die stenose des rückenmarkkanals
WO2000033845A1 (en) * 1998-12-07 2000-06-15 Nissan Chemical Industries, Ltd. Remedial agent for erectile dysfunction
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CN1259316C (zh) * 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
EP1389468A4 (en) 2001-05-23 2007-01-10 Tanabe Seiyaku Co COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2526586C (en) * 2003-09-09 2010-03-16 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
CN1897952B (zh) * 2003-12-26 2010-12-08 日产化学工业株式会社 中性白细胞增多抑制剂
CN100506230C (zh) * 2004-02-09 2009-07-01 日产化学工业株式会社 血管内膜增厚抑制剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2374805A4 (en) * 2008-12-25 2012-06-27 Nissan Chemical Ind Ltd PYRIDAZINE-3 (2H) -ONE HYDROCHLORIDE COMPOUND CRYSTALS AND METHOD FOR THE PRODUCTION THEREOF
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099573A1 (ja) 2010-02-12 2011-08-18 大正製薬株式会社 徐放性製剤
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3660016A1 (en) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
SI3030549T1 (sl) 2013-09-12 2019-08-30 Janssen Biopharma, Inc. Spojine piridazinona in njihove uporabe
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
EP4706758A3 (en) 2019-05-21 2026-05-06 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
EP0186817B1 (en) * 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
ES2149761T3 (es) * 1990-04-25 2000-11-16 Nissan Chemical Ind Ltd Derivado de piridazinona.

Also Published As

Publication number Publication date
EP0482208A1 (en) 1992-04-29
AU634655B2 (en) 1993-02-25
HU208124B (en) 1993-08-30
DE69132329D1 (de) 2000-08-24
AU7651191A (en) 1991-11-11
WO1991016314A1 (en) 1991-10-31
HU913497D0 (en) 1992-01-28
UA27031A1 (uk) 2000-02-28
DE69132329T2 (de) 2000-11-30
TW204348B (https=) 1993-04-21
DK0482208T3 (da) 2000-09-18
US5314883A (en) 1994-05-24
ES2149761T3 (es) 2000-11-16
ATE194835T1 (de) 2000-08-15
CA2053863C (en) 1996-10-29
RU2054004C1 (ru) 1996-02-10
ZA913134B (en) 1992-04-29
KR920701169A (ko) 1992-08-11
HUT60253A (en) 1992-08-28
EP0482208B1 (en) 2000-07-19
CA2053863A1 (en) 1991-10-26
US5318968A (en) 1994-06-07
JPH07107055B1 (https=) 1995-11-15
GR3034331T3 (en) 2000-12-29
US5202323A (en) 1993-04-13
EP0482208A4 (en) 1992-10-07
JPH07107055B2 (ja) 1995-11-15

Similar Documents

Publication Publication Date Title
KR970002876B1 (ko) 피리다지논 유도체
JPWO1991016314A1 (ja) ピリダジノン誘導体
US4978665A (en) 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JPH06135938A (ja) ３，６−ジ置換ピリダジン誘導体
JPWO1998008836A1 (ja) クロメン−３−カルボン酸誘導体
EP0376079A1 (en) 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A
KR100647726B1 (ko) 피리다진-3-온 유도체 및 이를 함유하는 의약
KR100255416B1 (ko) 약학적 활성을 갖는 피리다지논 유도체
CA1294273C (en) Sulphonamido 3-benzazepine derivatives as antiarrhythmic agents
US5605901A (en) Indane derivatives, processes for preparing the same and synthetic intermediate of the same
JPWO2008156208A1 (ja) ５−フェニル−３−ピリダジノン誘導体
EP0717734B1 (en) Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
EP0742211B1 (en) Pyridazinone derivatives
TW509692B (en) 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
FR2711992A1 (fr) Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
US4965266A (en) Heteroarylcarboxamide derivatives, process for preparing the same and pharmaceutical composition containing the same
JP3666042B2 (ja) ピリダジノン誘導体
SU1340587A3 (ru) Способ получени производных конденсированных бензопиронов или их фармацевтически приемлемых солей
JPS63139172A (ja) ４，５−ジヒドロ−６−（６−置換−２−ナフチル）−３（２ｈ）−ピリダジノン誘導体
CA2018956A1 (en) Benzisoquinoline derivatives
JP2517309B2 (ja) ベンゾヘテロ環誘導体
JPH068296B2 (ja) アミノクロマノール誘導体
JPH0676390B2 (ja) ピリダジノン誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19911106

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940609

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19911106

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970213

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19970822

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19970822

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010816

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20020806

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20030806

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20040809

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20050809

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20060810

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20070808

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20080808

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20090807

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20100811

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20100811

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term